|
gptkbp:instance_of
|
gptkb:Ophthalmology
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Xiidra
|
|
gptkbp:clinical_trial
|
gptkb:OPUS-1
gptkb:OPUS-2
Phase 3
LIFE-1
LIFE-2
|
|
gptkbp:clinical_use
|
twice daily administration
|
|
gptkbp:condition
|
chronic dry eye
|
|
gptkbp:contraindication
|
hypersensitivity to lifitegrast
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:drug_interactions
|
none known
|
|
gptkbp:effective_date
|
gptkb:2016
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:form
|
gptkb:cream
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xiidra
|
|
gptkbp:indication
|
signs and symptoms of dry eye disease
|
|
gptkbp:ingredients
|
gptkb:lifitegrast
|
|
gptkbp:invention
|
2029
patented
|
|
gptkbp:launch_date
|
gptkb:2016
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
gptkb:Lymphocyte_function-associated_antigen_1_(LFA-1)_antagonist
|
|
gptkbp:packaging
|
single-use vials
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmaceutical_class
|
immunomodulator
|
|
gptkbp:pharmacokinetics
|
minimal systemic absorption
|
|
gptkbp:price
|
approximately $500 per month
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:American_Optometric_Association
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:route_of_administration
|
topical
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
headache
blurred vision
eye irritation
dry eye
ocular discomfort
taste disturbance
foreign body sensation
conjunctival hyperemia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
dry eye disease
|
|
gptkbp:bfsParent
|
gptkb:Shire_plc
|
|
gptkbp:bfsLayer
|
5
|